These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 867485)

  • 41. Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen.
    Matis LA; Ruscetti SK; Longo DL; Jacobson S; Brown EJ; Zinn S; Kruisbeek AM
    J Immunol; 1985 Jul; 135(1):703-13. PubMed ID: 2582053
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Regulation of cytotoxic lymphocyte responses in vitro by alloantigen-activated spleen cells.
    Truitt GA; Rich RR; Rich SS
    J Immunol; 1977 Jul; 119(1):31-7. PubMed ID: 874322
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Studies on the induction of tolerance to alloantigens. II. The generation of serum factor(s) able to transfer alloantigen-specific tolerance for delayed-type hypersensitivity by portal venous inoculation with allogeneic cells.
    Fujiwara H; Qian JH; Satoh S; Kokudo S; Ikegami R; Hamaoka T
    J Immunol; 1986 Apr; 136(8):2763-8. PubMed ID: 2420865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Temperature control of lymphocyte-mediated cytotoxicity in vitro.
    Berke G; Sullivan KA
    Transplant Proc; 1973 Mar; 5(1):421-3. PubMed ID: 4695950
    [No Abstract]   [Full Text] [Related]  

  • 45. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
    Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of lymphocyte-mediated cytotoxicity against allogeneic tumor cells by concanavalin A in vivo.
    Anaclerio A; Waterfield JD; Möller G
    J Immunol; 1974 Sep; 113(3):870-5. PubMed ID: 4413847
    [No Abstract]   [Full Text] [Related]  

  • 47. Host reactivity against clonable tumor cells and the total tumor cell population, studied in a syngeneic murine lymphoma system.
    Gjedde SB
    Acta Pathol Microbiol Immunol Scand C; 1983 Apr; 91(2):101-8. PubMed ID: 6349250
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Functional properties of Ly 11.2 lymphocytes: a role for these cells in leukemia?
    Meruelo D; Paolino A; Flieger N; Dworkin J; Offer M; Hirayama N; Ovary Z
    J Immunol; 1980 Dec; 125(6):2719-26. PubMed ID: 6253569
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mechanism of blocking by hyperimmune serum of lymphocyte-mediated cytolysis of allogeneic tumor cells.
    Todd RF; Stulting RD; Berke G
    Cancer Res; 1973 Dec; 33(12):3203-8. PubMed ID: 4760536
    [No Abstract]   [Full Text] [Related]  

  • 50. Tumor sponge implantation: an in vivo method for studying syngeneic, primary antitumor lymphocyte responses.
    Vallera DA; Mentzer SJ; Maizel SE
    Cancer Res; 1982 Feb; 42(2):397-404. PubMed ID: 7055792
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhancement of tumor growth correlates with suppression of the tumor-specific cytolytic T lymphocyte response in mice chronically infected by Trypanosoma cruzi.
    Plata F
    J Immunol; 1985 Feb; 134(2):1312-9. PubMed ID: 2578157
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Syngeneic and allogeneic mouse lymphoma antisera: specificity, reaction with fetal antigen and protective capacity.
    Prager MD; Granatek CH; Ludden CM
    Isr J Med Sci; 1976; 12(4-5):325-33. PubMed ID: 939692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
    Townsend SE; Su FW; Atherton JM; Allison JP
    Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene.
    Hui KM; Sim T; Foo TT; Oei AA
    J Immunol; 1989 Dec; 143(11):3835-43. PubMed ID: 2584720
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunogenicity of tumor cells modified by trinitrobenzene suflonic acid (TNBS).
    Kedar E; Unger E; Galili N; Klein G; Asjo B; Bonavida B; Naor D
    Prog Clin Biol Res; 1976; 9():109-21. PubMed ID: 1030796
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic control of the induction of cytolytic T lymphocyte responses to AKR/Gross viral leukemias. I. H-2-encoded dominant gene control.
    Green WR
    J Immunol; 1984 May; 132(5):2658-64. PubMed ID: 6425409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sensitivity of tumour and normal cells to the effect of immune lymphocytes in vitro and some properties of target cells determing this sensitivity.
    Lavrovsky VA; Razvorotnev VA
    Folia Biol (Praha); 1976; 22(2):108-15. PubMed ID: 776718
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Spontaneous antilymphoma reaction of preleukaemic AKR mice is a non-T-cell killing.
    Gomard E; Leclerc JC; Levy JP
    Nature; 1974 Aug; 250(5468):671-3. PubMed ID: 4854374
    [No Abstract]   [Full Text] [Related]  

  • 59. Immunity to lymphoid tumors in syngeneic mice by immunization with mitomycin C-treated cells.
    Benjamini E; Fong S; Erickson C; Leung CY; Rennick D; Scibienski RJ
    J Immunol; 1977 Feb; 118(2):685-93. PubMed ID: 839074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunoprophylaxis and cytotoxic effector cells against EL 4 leukemia induced in syngeneic C57BL/6J mice by use of irradiated EL 4 cells.
    Johnson TS; Hudson JL; Feldman ME; Irvin GL
    J Natl Cancer Inst; 1975 Sep; 55(3):561-7. PubMed ID: 51089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.